We selected the surface protein chondroitin sulfate proteoglycan 4 (CSPG4) as target TA of our CAR.CIK-based strategy, since it has been reported to be functionally involved in processes of tumor growth, progression and metastatic spread, it is over expressed on cancer cells with limited distribution in normal tissues, and it has been detected on both differentiated cancer cells and cancer initiating cells in several types of solid tumors [33–36]. This evidence concerns the gene CSPG4 and neoplasm.